Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles BMC Infectious Diseases Year : 2014

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment

Domains

Infectious diseases
Fichier principal
Vignette du fichier
1471-2334-14-S2-P83.pdf (63.7 Ko) Télécharger le fichier
1471-2334-14-S2-P83.xml (6.33 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Ed. BMC  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-00995738

Submitted on : Friday, May 23, 2014-5:14:20 PM

Last modification on : Tuesday, October 19, 2021-10:59:04 PM

Long-term archiving on: Monday, August 25, 2014-11:36:16 AM

Download

Dates and versions

inserm-00995738 , version 1 (23-05-2014)

Identifiers

  • HAL Id : inserm-00995738 , version 1

Cite

Anne-Sophie Chantry, M Tching-Sin, Catherine Dhiver, Thierry Allegre, Jean-Marie Ruiz, et al.. Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment. BMC Infectious Diseases, 2014, 14 (Suppl 2), pp.P83. ⟨inserm-00995738⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-AMU
153 View
635 Download

Share

Gmail Facebook Twitter LinkedIn More